Key result
Semaglutide linked to ~22% lower medical costs in overweight or obese ASCVD patients.
Why the study?
Does semaglutide 2.4 mg reduce all-cause medical costs and healthcare resource utilization in patients with overweight or obesity and ASCVD?
Cohort (n=3,850)
Does semaglutide 2.4 mg reduce all-cause medical costs and healthcare resource utilization in patients with overweight or obesity and ASCVD?
Answers are grounded in this paper and cite their sources.
In a real-world US cohort of patients with overweight or obesity and ASCVD, semaglutide 2.4 mg was associated with significantly lower annual medical costs and healthcare resource utilization, driven primarily by reduced inpatient costs.
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown. AIMS: To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls. MATERIALS AND METHODS: This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models. RESULTS: 770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]). LIMITATIONS: Limitations inherent to retrospective claims analyses apply to this study. CONCLUSIONS: This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.
No takes yet. Share an insight, caveat, or question.
Michalak et al. (2025) conducted a cohort in Overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) (n=3,850). Semaglutide vs. Semaglutide-untreated controls was evaluated on All-cause medical costs (cost ratio 0.78, 95% CI 0.67, 0.89). Semaglutide was associated with 22% lower mean medical costs versus untreated controls in patients with overweight/obesity and ASCVD.
Synapse has enriched 10 related papers. Consider them for comparative context: